A groundbreaking study led by researchers in Finland has uncovered a profound and previously underestimated link between frontotemporal dementia (FTD) and epileptic seizures. The research, which represents one of the most comprehensive datasets of its kind globally, suggests that epilepsy is far more common in patients suffering from this specific form of memory disorder than the medical community had previously recognized. This discovery not only deepens the scientific understanding of the complex symptomatic profile of FTD but also highlights a critical need for revised protocols in the clinical monitoring and long-term treatment of patients.
The project was a collaborative effort coordinated by Neurocenter Finland, bringing together the expertise of the University of Eastern Finland and the University of Oulu. By analyzing a massive repository of real-world patient data, the research team was able to provide a clearer picture of the neurological landscape of FTD. The findings, which have significant implications for both diagnostic accuracy and patient quality of life, were recently published in the prestigious medical journal JAMA Neurology.
Frontotemporal dementia is a group of uncommon disorders that primarily affect the frontal and temporal lobes of the brain—areas generally associated with personality, behavior, and language. Unlike Alzheimer’s disease, which typically presents with memory loss as its earliest and most prominent symptom, FTD often manifests through dramatic changes in social conduct, emotional regulation, or communication abilities. Because the symptoms are so distinct, the discovery that epilepsy plays a major role in the disease’s progression adds a new layer of complexity to how the condition must be managed.
Epilepsy occurred years before the FTD diagnosis
One of the most striking revelations of the study is the timeline in which epilepsy appears. While it has long been established that epilepsy is a common comorbidity in Alzheimer’s disease, data regarding its connection to frontotemporal dementia has historically been scarce and inconsistent. This lack of information has often left clinicians without clear guidance on how to screen for or treat seizures in FTD populations.
To fill this information gap, the research team conducted an exhaustive analysis of medical records from the university hospitals of Kuopio and Oulu, covering the period between 2010 and 2021. The sheer scale of the study is notable: researchers screened 12,490 medical records to identify a cohort of 245 patients with FTD and 1,326 patients with Alzheimer’s disease. These groups were then compared against healthy controls to determine the relative prevalence of epilepsy across different neurological profiles.
The results were definitive. "Our results show that epilepsy is considerably more common among those with FTD than those with Alzheimer’s disease or in healthy controls," stated Doctoral Researcher Annemari Kilpeläinen, the lead author of the study and a medical specialist in neurology. This finding challenges the traditional hierarchy of dementia-related comorbidities, placing FTD at the forefront of concern regarding seizure activity.
Perhaps more startling was the timing of these seizures. The data revealed that in several instances, epilepsy was diagnosed as many as ten years before the patient received a formal diagnosis of frontotemporal dementia. This suggests that for some patients, epileptic activity may be one of the earliest indicators of the underlying neurodegenerative processes that eventually lead to FTD.
"It is noteworthy that epilepsy occurred in some patients with FTD already ten years before their dementia diagnosis," Kilpeläinen noted, adding that the prevalence was higher at every stage of the disease than what has been reported in previous international literature. The study assessed prevalence at multiple intervals, ranging from a decade prior to the diagnosis to five years after. As the disease progressed, so did the frequency of epilepsy; five years post-diagnosis, approximately 11% of FTD patients were found to have epilepsy.
The researchers also looked beyond formal epilepsy diagnoses, examining the use of anti-epileptic medications among the patient groups. They found that these medications were significantly more common in the FTD group, a factor that reinforces the reliability of the study’s conclusions. The correlation between the medication data and the diagnostic records provides a robust evidence base, suggesting that the higher prevalence is not a statistical anomaly but a widespread clinical reality.
Epilepsy might be left undiagnosed
The intersection of FTD and epilepsy presents a unique set of diagnostic hurdles. In a clinical setting, identifying seizures in a patient who is already experiencing the cognitive and behavioral shifts associated with FTD is notoriously difficult. The symptoms of frontotemporal dementia—such as sudden behavioral outbursts, repetitive movements, or transient lapses in communication—can closely mimic the presentation of certain types of epileptic seizures.
This symptomatic overlap often leads to a "masking" effect, where seizures are dismissed as part of the behavioral symptoms of dementia. Consequently, many patients may suffer from undiagnosed and untreated epilepsy for years. The danger of this oversight cannot be overstated; untreated epilepsy can lead to further cognitive decline, physical injury, and a more rapid deterioration of the patient’s overall health.
"Identifying epilepsy is important because its treatment can improve patients’ functional capacity and quality of life," explained Associate Professor Eino Solje, the project’s principal investigator and Director of the University of Eastern Finland (UEF) Brain Research Unit. When seizures are controlled through appropriate medication and management, the heavy burden of the disease can be somewhat alleviated, allowing patients to maintain their independence and engagement with their surroundings for a longer period.
Beyond the immediate clinical benefits of better diagnosis, the study opens up profound new avenues for scientific inquiry. The strong association between these two conditions suggests that they may share more than just a chronological link. Solje pointed out that the findings raise critical questions about the "pathophysiological mechanisms" at play in the brain. It is possible that the neurodegeneration seen in FTD and the electrical instability seen in epilepsy are driven by the same underlying cellular or molecular changes.
"Knowledge about the association between epilepsy and FTD raises new research questions: do these diseases share some pathophysiological mechanisms and could some FTD symptoms be caused by alterations in the specific electrical systems of the brain," Solje said. If certain behavioral or cognitive symptoms of FTD are actually the result of localized electrical disturbances—essentially "micro-seizures" or subclinical activity—it could revolutionize the way these symptoms are treated, moving toward therapies that stabilize the brain’s electrical environment.
An extensive research project brings together different fields of science
The success of this study is attributed to its multi-disciplinary and collaborative nature. It was not merely a medical inquiry but a broad-based project that utilized exceptionally extensive real-life patient data integrated with unique national registers. This "big data" approach allowed the researchers to track patient journeys over a decade, providing a level of longitudinal insight that smaller clinical trials often lack.
The project fostered a deep cooperation between the University of Oulu and the University of Eastern Finland, merging their respective strengths in neurology and data science. Furthermore, the initiative reached across traditional academic boundaries, involving experts from both the medical and legal fields. This interdisciplinary perspective is crucial when dealing with neurodegenerative diseases, as the diagnosis of both dementia and epilepsy carries significant legal and ethical implications, ranging from driving privileges to the patient’s capacity to make healthcare decisions.
The involvement of the university hospitals in Kuopio and Oulu was also central to the study’s impact. Both institutions are recognized members of the international European Reference Network EpiCARE, a prestigious group of centers dedicated to the treatment and research of rare or complex epilepsies. This connection ensures that the findings from the Finnish study will be integrated into a broader European context, potentially influencing clinical guidelines across the continent.
By highlighting the high prevalence of epilepsy in FTD, the study sends a clear message to the global medical community: neurological assessments for dementia must be more holistic. Clinicians are encouraged to maintain a high index of suspicion for epilepsy when treating FTD patients, particularly when symptoms appear that do not fit the typical behavioral patterns of the disease.
As the population ages and the incidence of neurodegenerative disorders rises, understanding the interplay between different neurological conditions becomes increasingly vital. This study serves as a cornerstone for future research, suggesting that by treating the brain’s electrical health, we may be able to provide better care and a higher standard of living for those navigating the challenges of frontotemporal dementia. The research team hopes that these findings will lead to earlier interventions, more accurate diagnoses, and ultimately, a better understanding of the mysterious "electrical systems" that govern the human mind.
